UPDATE: Citigroup Raises PT on MedAssets from $15 to $16
Citigroup reiterated a Neutral rating on MedAssets (NASDAQ: MDAS) and raised its price target from $15 to $16.
Citigroup wrote, “We expect MDAS shares to be strong tomorrow and admit that we missed a recent opportunity to get more positive on the shares. We maintain our Neutral rating, and would look to get more positive should the shares come in or we find further upside to our estimates is possible. We are raising our target price to $16 from $15, reflecting 15x our revised 2012 EPS estimate.”
MedAssets closed at $12.85 on Wednesday.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.